Kat Kozyrytska Cell Therapy Manufacturability Program

Kat is passionate about making therapies personalized and accessible to more patients faster. She has founded Cell Therapy Manufacturability Program, a precompetitive consortium focused on reducing development and manufacturing timeline and costs and on accelerating standardization in cell therapies. While unlocking the power of AI and large, comprehensive data sets, Kat leverages innovations in Decentralized AI to bring data privacy, confidentiality, security, and control to biomanufacturing to protect biotech and pharma IP and know-how. In addition to the enterprise-level privacy, Kat is an advocate for patient and donor rights to privacy and control of their data. Kat obtained her Bachelor's degree from MIT, did her graduate work at Stanford, commercialized technology innovation across modalities at Thermo Fisher Scientific, Sartorius, and others for over 10 years, and helps companies bring their innovative technologies to market.